Immunovative Inc. announced that on January 8, 2013, it received from Immunovative Therapies Ltd. a notice that purports to terminate effective immediately the license agreement dated as of December 9, 2011, between the company and ITL. The notice alleges numerous purported breaches of the license agreement, mainly with respect to the administration and timing of payments from the company to ITL. It also demands immediate payment of approximately $4.15 million from the company to ITL for what it claims to be damages suffered by ITL.